biotech · Generalized Myasthenia Gravis · Leukemia, Myeloid, Acute · VOR
Vor Biopharma
Vor Biopharma is a biotech organization headquartered in Cambridge, USA. It trades on NYSE under ticker VOR. Primary therapeutic focus areas include Generalized Myasthenia Gravis, Leukemia, Myeloid, Acute, Systemic Lupus
Cambridge, USA HQ
110 Employees
Public company Type
VOR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Employees
- 110
- Programs
- 6
- Drugs
- 4
- Patents
- 12
Telitacicept
Phase 3 · mab · Primary Sjogren's Disease
Telitacicept for Primary Sjogren's Disease is a Phase 3 program (mab) at Vor Biopharma with 1 ClinicalTrials.gov record(s).
Internal code RC18G007
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vor Biopharma
- Phase
- Phase 3
- Modality
- mab
- Indication
- Primary Sjogren's Disease
- Status
- active
- Trials
- 1